TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MedifoamⓇ and BetafoamⓇ in Pressure Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged at least 19 years old as of the consent date~2. Pressure ulcer of National Pressure Ulcer Advisory Panel (NPUAP) Stage III at screening~3. Pressure ulcer size of 3-10 cm2 at screening~4. Written consent provided by the subject or representative~Exclusion Criteria:~1. Any study ulcer of NPUAP Stage I, II or IV~2. Diabetic ulcer or venous ulcer (or stasis ulcer)~3. Past history of surgical treatment within 1 year or irradiation at the target pressure ulcer within 1 year~4. Hypersensitivity reaction to this product or povidone iodine~5. Hyperthyroidism or thyroid disorder requiring drug treatment~6. Signs of a current underlying systemic infection (sepsis/bacterial infection/tuberculosis) or cellulitis or osteomyelitis~7. Type 1 diabetes~8. Current malnutrition~9. Heavy smoker: Current smoking level of ≥1 pack (20 cigarettes)/day of tobacco~10. Drug or alcohol addiction~11. Requirement of immune-suppressants during the study, or current chemotherapy or radiotherapy~12. Application of other investigational product/medical device within 1 month prior to the investigational device application~13. Pregnant or breast-feeding women~14. Other renal, hepatic, neurological or immunological disorder that may interfere with the wound healing process, at the discretion of the Investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foam Dressing (Type: OTHER): Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
- Foam Dressing with Povidone Iodine (Type: OTHER): Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with locally advanced, metastatic or recurrent pancreatic ductal adenocarcinoma (PDAC)~2. Patients who are being treated and/or followed at Indiana University Simon Cancer Center or Eskenazi Hospital~3. ECOG PS 0-2 at the time of study enrollment~4. Life expectancy \> 6 months~5. Adequate organ function~   * As defined by the following laboratory values at study entry:~  * Hemoglobin ≥ 9 g/dL (transfusions are acceptable)~  * ANC ≥ 1.5 x 109/L~  * Platelets ≥ 100 x 109/L~  * Creatinine ≤ 1.5 x ULN, or creatinine clearance ≥ 50 mL/min (estimated by Cockcroft-Gault or measured)~  * Total bilirubin ≤ 1.5 x ULN~  * AST/ALT ≤ 3 x ULN~6. Willingness to sign informed consent and to perform pulmonary function tests (PFTs) and strain echocardiogram~Exclusion Criteria:~1. Known history of congestive heart failure (NYHA class III or IV)~2. Reported weight loss more than 10% within 3 months prior to study entry~3. Known history of pulmonary disease such as pulmonary hypertension, chronic obstructive pulmonary disease requiring medical management or previous lung resection~4. Current liver cirrhosis~5. Current chronic kidney disease~6. Inability or refusal to receive systemic therapy~7. Inability to comply with pulmonary function tests (PFTs)~8. Large volume ascites interfering with ability of respiration~9. Current unstable angina (or history of within last 6 months)~10. Recent myocardial infraction (within last 6 months)~11. Recent pneumothorax (within last 6 months)~12. Uncontrolled hypertension (per investigator's discretion)~13. Lung biopsy within one week from PFT~14. Recent surgery \< 4 weeks

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Fentanyl Versus Oral Morphine Sulfate in the Treatment of Pain in Pediatric Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged between 4 years old and 15,3 years old~* Acute pain in traumatic context with a suspicion of fracture for patient \<7years old : feeling Pain \>6/10 defined with a face analogue scale and a visual analogic scale (the difference between the scales is not \<10 points)~* For patients \>7 years old : feeling pain \>6 points and defined thanks to a visual analogic scale~* Informed consent form signed by parents~* Beneficiary of an european health protection~Exclusion Criteria:~* Antalgic ( II or III) within 4 hours before the inclusion~* Allergic or non-indication of fentanyl~* Allergic or contraindication of morphine sulfate~* Pre existing peripheral intravenous catheter~* Traumatic brain injury~* Nasal traumatic

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal fentanyl + Oral placebo (Type: EXPERIMENTAL): Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
- Oral morphine + Intranasal placebo (Type: ACTIVE_COMPARATOR): Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men undergoing a standard of care radical prostatectomy for prostate cancer.~* Aged \> 40 years old.~* Men who have a serious prostate obstruction, are excluded due to the difficulty of catheter insertion.~Exclusion Criteria:~* Women are excluded as they do not have a prostate gland.~* Minors are excluded as prostate cancer is generally found only in men aged \> 40 years old

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Mecillinam for Treatment of Genital Chlamydia Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Proficient in oral and written Norwegian~* Positive NAAT in first void urine for Chlamydia trachomatis~* Negative NAAT in first void urine for Mycoplasma genitalium~* Heterosexual male~* Asymptomatic~Exclusion Criteria:~* Known allergies for mecillinam, penicillin or cephalosporines~* Metabolic anomalies of aciduric type~* Apparent underweight~* Use of mecillinam within the last two months~* Under treatment with Valproat, other anti-infective drugs, immuno-modulating medication~* In the opinion of investigator,obvious reasons why patient will fails to adhere to treatment and follow-up protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pivmecillinamhydrochlorid (Type: EXPERIMENTAL): Selexid 400 mg x 3 , 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be ≥ 18 years of age.~* Histologically proven pancreatic adenocarcinoma. .~* Deemed to have achieved stability following ≥16 weeks of platinum based therapy, in the opinion of an investigator~* Considered a candidate for PARP inhibitor therapy, with or without additional agents, either on a clinical trial or as part of clinical care.~* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.~* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician~* Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [18F]FluorThanatrace ([18F]FTT) (Type: OTHER): 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age ≥ 18 years~* Diagnosis of primary warm antibody hemolytic anemia (AIHA).~* Hemoglobin \< 100g/L~* Refractory to or relapsed after at least 2 prior treatment line.~* ECOG performance status ≤ 2~* Willing and able to comply with the requirements for this study and written informed consent.~Exclusion Criteria:~* Neutrophils counts \< 0.5×10\^9/L or platelet counts \< 50 x 10\^9/L~* Diagnosis of any of the following diseases: Cold agglutinin disease, cold agglutinin syndrome, mixed AIHA, paroxysmal cold hemoglobinuria (PCH).~* Diagnosis of the active stage of the connective tissue or systemic autoimmune rheumatic diseases (SARDs)~* History of lymphoproliferative neoplasms~* Had other inherited or acquired hemolytic diseases.~* Secondary AIHA caused by drugs or infection~* Previously received organ or stem cell transplantation.~* Had malignant tumor within 5 years before enrollment, exclusive of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial tumor, cervical carcinoma in situ or other indolent tumors~* Patients with HBV, HCV, HIV or other infections that require treatment.~* Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values~* Renal impairment: creatinine clearance \<60ml/min~* Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, including clinically significant cardiac diseases, refractory hypertension, metabolic disorders and other diseases that seriously affect the function of the gastrointestinal tract.~* Had a history of any psychiatric diseases, cerebrovascular disease or cognitive sequelae of head injury.~* Received rituximab in 6 weeks before enrollment.~* Received attenuated vaccine 4 in weeks before enrollment~* Participation in another clinical trial within 4 weeks before the start of this trial~* Have an allergy to Linperlisib or any other part of this medicine.~* Previously treated with other PI3Kδ inhibitor.~* Pregnant or breast-feeding patients~* Patients considered to be ineligible for the study by the investigator for reasons other than the above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PI3K Delta Inhibitor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 14-35~* Prior to injury, participant fulfilled ACSM's guidelines for regular aerobic activity (30 minutes of moderate-intensity exercise 5 days per week or 20 minutes of vigorous exercise 3 days per week) prior to injury.~* Diagnosed with a sport related concussion within 14 days of injury in the window of 3-30 days prior to completing the first study visit, and also being a single episode.~* Participants referred to exertion therapy after a trained clinician from University of Pittsburgh Medical Center (UPMC) Sports Medicine Concussion Program has interpreted neurocognitive, vestibular, and clinical interview outcomes~Exclusion Criteria:~* History of brain surgery or traumatic brain injury(based on Glasgow Coma Scale of \<13)~* History of neurological disorder (seizure disorder, epilepsy, brain tumors or malformations)~* Current history of pre-existing vestibular disorder \[benign paroxysmal positional vertigo (BPPV), labyrinthitis or vestibular neuritis\]~* Previous diagnosis of ocular motor condition (Ocular motor apraxia)Currently taking anticoagulant, beta-blockers, and anticonvulsant prescription medication~* Diagnosed with a cardiac, peripheral, or cerebrovascular disease (type 1 or 2 diabetes, or renal disease.~* Experienced chest pain or shortness of breath while at rest or with mild exertion.~* Lose balance because of dizziness or have lost consciousness (aside from concussion) from exertion~* Diagnosed with or taking medication for a chronic medical condition~* Currently have a mental or physical impairment exacerbated by physical activity, leading to the inability to complete 30 minutes of moderate to vigorous exercise~* Been told by a doctor to only conduct physical activity under medical supervision.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Aerobic (treadmill) Exercise (Type: ACTIVE_COMPARATOR): Participants will wear a heart rate monitor and complete the Buffalo Concussion Treadmill Test
- Dynamic Exercise (Type: EXPERIMENTAL): Participants will wear a heart rate monitor and complete a dynamic exertion assessment that incorporates directional changes that incrementally increases in exercise intensity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Able to read text on a computer screen~* Able to understand and remember instructions concerning participation~Exclusion Criteria:~* Unable to give informed consent~* Unable to understand and follow instructions~* Have abnormal tone or uncontrolled movements in the head-and-neck that would interfere with EEG recordings~* Known to have photosensitive epilepsy~* Open head lesions or sores

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pilot Testing (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 65 or older~* Diagnosis of a malignancy requiring chemotherapy as part of intent to cure oncologic therapy or diagnosis of prostate cancer requiring 6 months or less of androgen deprivation therapy as part of oncologic treatment.~* A planned oncologic regimen of at least 3 months but not more than 9 months excluding surgery. This will include most solid tumors and lymphoma.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Prior treatment for malignancy other than basal or squamous cell skin cancer~* Evidence of metastatic disease~* Individuals with acute and chronic leukemias and individuals receiving anti-estrogen therapy only as their primary oncologic treatment.~* Dementia, psychotic condition or other central nervous system impairment limiting compliance~* Medical conditions that limit ability to walk at least 4 meters.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Individuals age 65 or older (Type: None): Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation in Ocular Lesions of Behcet's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Behcet's Disease~* Fulfilling the International Criteria for behcet's Disease (ICBD)~* Ocular lesions with retinal vasculitis~* Resistant to at least 3 months of combination therapy with pulse cyclophosphamide (1g/monthly), azathioprine (3 mg/kg/daily), and prednisolone 0.5 mg/kg/daily~* Visual acuity not less than 4 meters finger count~* Retinal edema confirmed by color photography and OCT~Exclusion Criteria:~* No Vision~* Active posterior uveitis~* Fundus not visible

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Behcet's Disease with ocular lesions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy